Objectives: To summarize the evidence underlying the non-surgical management of patients with complicated parapneumonic effusions (CPPE) or empyemas. Data source: All articles published in PubMed according to their relevance with the subject were identified. Results and conclusions: There is a lack of powered randomized controlled studies comparing medical and surgical approaches to CPPE/empyemas in adults. In addition to antibiotics for an unspecified period of time, CPPE/empyemas can initially be treated with a therapeutic thoracentesis (which can be repeated if necessary), the insertion of a small-bore chest catheter under ultrasound guidance, or the administration through the catheter of fibrinolytics alone, saline alone or fibrinolytics in combination with either saline or deoxyribonuclease. These conservative measures resolve more than 90% of the cases, thus making a rescue surgery unnecessary.
| IN TRO DUCT IO N
A parapneumonic effusion (PPE) is defined as any pleural effusion associated with pneumonia, lung abscess or bronchiectasis. PPE is one of the most frequent etiologies of pleural fluid accumulation. For instance, in one study PPE was the third leading cause of pleural effusion, after cancer and heart failure, among 3077 consecutive patients who were subjected to a diagnostic thoracentesis. 1 It accounted for 19% of all the cases and 23% of all exudates.
1 PPE frequently complicates pneumonia. A retrospective review of 4715 patients with community-acquired pneumonia admitted to 2 Spanish hospitals showed that 19% had an accompanying pleural effusion on a chest radiograph. 2 Most of these PPE resolved without any specific therapy directed towards the effusion, but around 30% of patients did require pleural drainage. Obviously, when more sensitive radiological techniques are used, the prevalence of PPE rises. In a prospective multicentre study comprising 229 patients with community-acquired pneumonia, 54% had basal pleural effusions with a median volume of 50 mL on transthoracic ultrasonography. 3 The possibility of a PPE should be considered in all patients with pleural effusion and fever; and particularly, in those patients with pneumonia who fail to respond to antibiotics, that is, those who do not achieve clinical stability or a 50% reduction of serum C-reactive protein (CRP) by day 3 or 4. 4 Mortality from bacterial pleural infection is not negligible. Data from a Danish registry showed that the overall 1-month mortality rate of 6878 patients with thoracic empyema was about 10%, although it varied according to age and comorbidity, ranging from only 1.2% in patients aged 40 years or less up to 20.2% in those 80 years or more. 5 Whether or not to drain the pleural space is the primary decision in managing a patient with a PPE. The term uncomplicated PPE (UPPE) refers to those effusions that resolve with antibiotics alone. A complicated PPE (CPPE) denotes one that requires pleural drainage for cure, in addition to antibiotics. Empyema, the term used for the most advanced stage of PPE, indicates pus in the pleural space and must always be drained. In clinical practice, many CPPE are empyemas, though the challenge is to identify those patients whose fluids are non-purulent, yet for whom drainage will ultimately be necessary. 6 This narrative review offers arguments for managing CPPE/empyemas with minimally-invasive procedures, thus avoiding thoracoscopy or surgery in the great majority of clinical situations.
| ANTI BI O TI C THE RAP Y I N P ARAP NEUM ONI C E F F US I ONS
PPE and empyema exhibit a different bacteriology from that of pneumonia. In pneumonia, the most commonly identified bacterial pathogens are Streptococcus pneumoniae, Haemophilus influenzae and atypical microorganisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella). In contrast, in community-acquired PPE/empyemas streptococcal species (largely viridans streptococci, followed by pneumococcus) account for about half of the isolates, while in hospital-acquired infections staphylococci (mainly methicillin-resistant S. aureus), aerobic Gram-negative organisms (Enterobacteriaceae) and enterococci predominate. 1, 8, 9 Anaerobes are identified in 7%-16% of pleural infections. 1, 8, 9 Culture-positive pleural fluid samples are found in around 30% of PPE in general 10 and 60% of empyemas in particular. 11 Although practice may vary markedly, a potentially suitable prescription of empirical antibiotic therapy in community-or hospital-acquired PPE/empyemas is shown in Table 1 . The duration of therapy has not been well established, but most experts recommend at least 3 weeks for CPPE or empyemas. 11 
| WH EN S HO ULD A P ARAP NEUM ONI C E F F US I ON BE DR AI NED?
The guidelines of 3 prominent scientific societies agree that pleural fluids with a purulent appearance, positive Gram's stains or cultures, or a pH < 7.20 are unlikely to resolve without prompt pleural space drainage. [12] [13] [14] Two of the guidelines also recommend drainage for large (1/2 hemithorax) or loculated PPE.
12,13
A recent retrospective review of 641 consecutive patients with PPE, of whom 163 had empyemas, 230 non-purulent CPPE and 248 UPPE, weighed the indicators of chest drainage among different clinical, radiological (loculations or separations were not included) and pleural fluid variables. 10 A multivariate logistic regression analysis selected effusions occupying half or more of the hemithorax [odds ratio (OR) 22 .5] and a pleural fluid pH 7.15 (OR 8.9) as the only significant independent predictors of CPPE. In addition to these 2 parameters, a pleural fluid CRP >100 mg/L (OR 3.9) also had discriminatory properties when only non-purulent PPE were considered.
| HO W S H OULD A P AR AP NE UMO NI C EF F U S IO N BE DR AI NED U S IN G MI N IM ALL Y-I NVA S I VE P RO CEDU RES ?
The options for pleural space drainage of CPPE/empyemas listed in order of increasing invasiveness are: (1) repeated therapeutic thoracenteses, (2) insertion of a chest catheter, (3) administration of intrapleural therapies through a chest catheter [eg, fibrinolytics, deoxyribonuclease (DNase), saline or a combination], (4) pleuroscopy with adhesiolysis and/or decortication and (5) open thoracotomy with decortication. The latter 2 encompass the term 'surgical' management of CPPE/empyemas, which is out of the scope of this review. A recent Cochrane review that included 8 randomized controlled trials (only 2 in adults) with a total of 391 participants found no statistically significant difference in mortality (primary outcome) between primary surgical and nonsurgical approaches to pleural empyema. 15 However, mortality data were limited because only one study reported deaths in both treatment arms and, therefore, the quality of evidence was considered, at best, moderate.
| Therapeutic thoracenteses
Iterative thoracentesis is time-tested treatment modality that has, until recently, received relatively little consideration. The sum of 4 series totalling 250 patients with CPPE/empyemas subjected to daily thoracenteses showed that 76% of the cases were successfully treated after a median number of 3 procedures. [16] [17] [18] [19] In the larger study, which included 79 patients, of whom 66% had empyemas, it was reported that if the volume of the first thoracentesis was 450 mL or more, the risk of failure with this strategy significantly increased. 19 In other words, it is better to consider this technique only in patients with small to moderate pleural effusion sizes. Otherwise, the insertion of a chest tube is more practical. Repeated therapeutic thoracenteses could potentially be used in association with intrapleural therapies (eg, saline), though clinical trials are needed to ascertain the role of this combination.
| Chest tubes
Tube thoracostomy is the most common drainage modality for CPPE/empyemas. Its optimal size is still a matter of debate. Although the tendency has been to use large-bore tubes (>14F and, particularly >20F), a prospective nonrandomized study of 405 patients who participated in the Multicentre Intrapleural Sepsis Trial (MIST) found that there was no significant difference in the percentage of patients who either died or required thoracic surgery relative to the chest tube size (size <10F, 36%; size 10-14F, 36%; size 15-20F, 40% and size >20F, 44%; P 5 .27). 20 Since smaller tubes are easier to insert and less painful to the patient, it can be inferred that they should be the initial treatment of choice for pleural infection.
| Intrapleural fibrinolytics and/or deoxyribonuclease
The theory behind the use of intrapleural fibrinolytics is that they destroy the fibrin septations, and thus facilitate the drainage of the pleural space. On the other hand, DNase reduces pus viscosity (which is believed to arise from DNA liberated by degranulated leukocytes) and consequently may also enhance drainage. 21 The used drugs and dosage regimens are reported in Table 2 .
Initial encouraging results on the efficacy of fibrinolytics were tempered by a landmark multicentre trial (MIST1) of 430 patients with pleural infection (>80% having empyemas) who were randomized to receive either intrapleural streptokinase or saline (placebo) via chest tube. 22 At 3 months after randomization, there was no benefit from streptokinase in terms of rate of surgery (16% and 14% respectively), death (16% and 14% respectively) or the composite (31% and 27% respectively; all P values non-significant).
With the hypothesis that either streptokinase was an inappropriate fibrinolytic or the use of fibrinolytics alone was the wrong strategy, a new multicentre trial, named MIST2, was designed. 23 The MIST2 study randomized 210 patients with CPPE (about half with visible purulent fluids) to one of the following 4 regimens administered via chest tube (size <15F in >80% of the cases): t-PA plus placebo, DNase plus placebo, t-PA plus DNase and double placebo. The combination of t-PA and DNase resulted in a significantly greater reduction in pleural opacity on chest radiographs at day 7 postrandomization than did the other regimens. When the secondary endpoints were examined, the patients who received the combination had a significant decrease in surgical referrals at 3 months (4%), in comparison with the t-PA (6%), DNase (39%) and placebo (16%) groups. Mortality at 3 months did not differ significantly among groups. Although the results of the 2 multicentre studies from the United Kingdom 22, 23 showed no convincing advantages of fibrinolytics over placebo (unless combined with DNase), 2 meta-analyses of 7 and 10 randomized controlled trials, 24, 25 which included the MIST1 and MIST2 studies, concluded that fibrinolytics alone were potentially effective in reducing the need for surgery (odds ratio 5 0.24 in the most recent one 25 ). If intrapleural fibrinolytics alone are to be used in treatment, the only randomized prospective study which compared urokinase and t-PA in 99 patients with pleural infection (34% empyemas) favoured the former, particularly in the subgroup of non-purulent CPPE. 26 Overall, the success rate of each fibrinolytic was 95.8% and 80.4% respectively, and only 3% of patients eventually needed surgical therapy. Currently, not generally applied in practice.
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Since its original description, the benefits of the t-PA and DNase combination have been further supported by other studies. The sum of 8 series, totalling 505 patients with pleural infection (47.5% with empyemas) who were treated with intrapleural t-PA plus DNase shows that 91% cured without a rescue surgical intervention. 23, [27] [28] [29] [30] [31] [32] [33] In addition, this therapy is safe, with a mean rate of non-fatal pleural bleeding of 3.4%.
| Saline lavage
Recently, a new intrapleural therapy has reported benefits for patients with CPPE/empyemas. It consists of the mechanical lavage of the pleural cavity through either irrigation or manual instillation of saline with both via chest tube. In the Pleural Irrigation Trial (PIT), saline pleural irrigation (250 mL bags of 0.9% sodium chloride administered by gravity 3 times per day for 3 days) through a 12F chest catheter was compared to chest catheter alone. 34 A total of 35 patients with pleural infection (40% empyemas) were randomized, and those receiving saline had a significantly greater reduction in computed tomography pleural collection volume at day 3 than those receiving standard care (32.3% vs 15.3%, P 5 .04). Also, fewer patients in the irrigation group were referred for surgery (11% vs 47%, P 5 .03). There was no difference in length of hospital stay or mortality among groups.
In a recent retrospective study, 23 patients with CPPE/ empyemas who received saline flushing (ie, manual instillation/aspiration maneuvers with normal saline solution) plus urokinase through small-bore chest catheters were compared with 39 who were only treated with fibrinolytics. 35 Intrapleural saline flushes reduced fibrinolytic therapy (a single dose of urokinase being sufficient in 44% vs 15%, P 5 .019), chest tube duration (2 vs 5 days, P < .01) and length of hospital stay (6 vs 8 days, P 5 .011) as compared with urokinase alone. A large definitive randomized trial is needed to evaluate the effectiveness of this safe, inexpensive and welltolerated treatment.
| CO NCL US I ONS
Undoubtedly, surgical procedures might be required in some patients with CPPE/empyema, but whether they should be recommended exclusively when medical therapy fails or in all upfront situations have not been addressed in adequately powered randomized trials. However, the insertion of a smallbore catheter under ultrasound guidance with the administration of different intrapleural therapies (ie, fibrinolytics alone, fibrinolytics plus DNase, saline alone or saline plus fibrinolytics) is effective in more than 90% of the cases, thus making rescue surgeries for them unnecessary. It is also plausible to initially perform a therapeutic thoracentesis (as well as diagnostic), with an optional saline lavage, whenever the PPE patient has sufficient pleural fluid, but not reaching a large volume (in which case it is better to choose a chest catheter).
It is important that the definitive therapy to be followed be applied within 7-10 days of the initial identification of the PPE. A sequential algorithmic management of PPE, which represents an experience-based personal view and the current protocol in our centre, is depicted in Figure 1 .
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